Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 754.49

-3.3%

Feb 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (642)	4/19/2002 11:39:06 PM
From: Miljenko Zuanic	Read Replies (1) of 3561

<<However, patient compliance with this therapy is expected to be low because CNTF is a protein and must, therefore, be administered by daily injections. We are developing Physiogenomics-based approaches and unique medicinal chemistry strategies for identification of an orally active, small molecule mimic of CNTF.>> Insulin is also administrated as MULTIPLE daily injection, and total sale is + 3B annually. A still have a chance as once-a week (or twice a week) PEG-formulation, or oral EMIS formulation. Good luck with oral mimetic A. REGN tried this, I think. gp-130 is involved in multiple receptor-ligand interaction, so one have to discriminate good from evil. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next